Clinical characteristics associated with racial disparities in endometrial cancer outcomes: A surveillance, epidemiology and end results analysis

Gynecologic Oncology

Volumn 148, Issue 2, 2018, Pages 349-356

  Sud, Shivani ^a   Holmes, Jordan ^a   Eblan, Michael ^a   Chen, Ronald ^a,b   Jones, Ellen ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Healthcare disparities; Hysterectomy; Radiotherapy; SEER program; Uterine neoplasm

Indexed keywords

ADULT; AGED; ARTICLE; BLACK PERSON; BRACHYTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CAUCASIAN; CLINICAL FEATURE; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HOUSEHOLD INCOME; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; RADICAL HYSTERECTOMY; ADOLESCENT; AFRICAN AMERICAN; CANCER REGISTRY; ENDOMETRIUM TUMOR; EPIDEMIOLOGY; ETHNOLOGY; HEALTH CARE DISPARITY; HEALTH DISPARITY; MIDDLE AGED; MORTALITY; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HUMANS; HYSTERECTOMY; MIDDLE AGED; MORTALITY; SEER PROGRAM; SOCIOECONOMIC FACTORS; UNITED STATES; YOUNG ADULT;

EID: 85038869306     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2017.12.021     Document Type: Article

References (32)

1. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016: cancer statistics, 2016. CA Cancer J. Clin. 66 (2016), 7–30, 10.3322/caac.21332.
2. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, (based on November 2015 SEER data submission, posted to the SEER web site, April 2016). n.d.
3. Allard, J.E., Maxwell, G.L., Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer. Cancer Control. J. Moffitt Cancer Cent. 16 (2009), 53–56.
4. Cote, M.L., Ruterbusch, J.J., Olson, S.H., Lu, K., Ali-Fehmi, R., The growing burden of endometrial cancer: a major racial disparity affecting Black women. Cancer Epidemiol. Biomark. Prev. 24 (2015), 1407–1415, 10.1158/1055-9965.EPI-15-0316.
5. Wright, J.D., Fiorelli, J., Schiff, P.B., Burke, W.M., Kansler, A.L., Cohen, C.J., et al. Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer 115 (2009), 1276–1285, 10.1002/cncr.24160.
6. Duncan, M., Seagroatt, V., Goldacre, M., Cancer of the body of the uterus: trends in mortality and incidence in England, 1985–2008: uterine cancer incidence and mortality. BJOG Int. J. Obstet. Gynaecol. 119 (2012), 333–339, 10.1111/j.1471-0528.2011.03201.x.
7. Wartko, P., Sherman, M.E., Yang, H.P., Felix, A.S., Brinton, L.A., Trabert, B., Recent changes in endometrial cancer trends among menopausal-age US women. Cancer Epidemiol. 37 (2013), 374–377, 10.1016/j.canep.2013.03.008.
8. Friberg, E., Orsini, N., Mantzoros, C.S., Wolk, A., Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50 (2007), 1365–1374, 10.1007/s00125-007-0681-5.
9. Madison, T., Schottenfeld, D., James, S.A., Schwartz, A.G., Gruber, S.B., Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. Am. J. Public Health 94 (2004), 2104–2111.
10. Randall, T.C., Differences in treatment and outcome between African-American and White women with endometrial cancer. J. Clin. Oncol. 21 (2003), 4200–4206, 10.1200/JCO.2003.01.218.
11. Hicks, M.L., Phillips, J.L., Parham, G., Andrews, N., Jones, W.B., Shingleton, H.M., et al. The National Cancer Data Base report on endometrial carcinoma in African-American women. Cancer 83 (1998), 2629–2637.
12. Farley, J., Risinger, J.I., Rose, G.S., Maxwell, G.L., Racial disparities in blacks with gynecologic cancers. Cancer 110 (2007), 234–243, 10.1002/cncr.22797.
13. NCCN Clinical practice guidelines in oncology (NCCN GuidelinesTM) uterine neoplasms version 1. 2017. NCCN.org, http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. n.d.
14. Rauh-Hain, J.A., Buskwofie, A., Clemmer, J., Boruta, D.M., Schorge, J.O., del Carmen, M.G., Racial disparities in treatment of high-grade endometrial cancer in the Medicare population. Obstet. Gynecol. 125 (2015), 843–851, 10.1097/AOG.0000000000000605.
15. Olson, S.H., Atoria, C.L., Cote, M.L., Cook, L.S., Rastogi, R., Soslow, R.A., et al. The impact of race and comorbidity on survival in endometrial cancer. Cancer Epidemiol. Biomark. Prev. 21 (2012), 753–760, 10.1158/1055-9965.EPI-11-0735.
16. Fine, J.P., Gray, R.J., A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc., 94, 1999, 496, 10.2307/2670170.
17. Creutzberg, C.L., van Putten, W.L., Koper, P.C., Lybeert, M.L., Jobsen, J.J., Wárlám-Rodenhuis, C.C., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet Lond. Engl. 355 (2000), 1404–1411.
18. Keys, H.M., Roberts, J.A., Brunetto, V.L., Zaino, R.J., Spirtos, N.M., Bloss, J.D., et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 92 (2004), 744–751, 10.1016/j.ygyno.2003.11.048.
19. ASTEC/EN.5 Study Group, Blake, P., Swart, A.M., Orton, J., Kitchener, H., Whelan, T., et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet Lond. Engl. 373 (2009), 137–146, 10.1016/S0140-6736(08)61767-5.
20. Nout, R.A., Smit, V.T.H.B.M., Putter, H., Jürgenliemk-Schulz, I.M., Jobsen, J.J., Lutgens, L.C.H.W., et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet Lond. Engl. 375 (2010), 816–823, 10.1016/S0140-6736(09)62163-2.
21. Nout, R.A., Putter, H., Jürgenliemk-Schulz, I.M., Jobsen, J.J., Lutgens, L.C.H.W., van der Steen-Banasik, E.M., et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 27 (2009), 3547–3556, 10.1200/JCO.2008.20.2424.
22. Galaal, K., Al Moundhri, M., Bryant, A., Lopes, A.D., Lawrie, T.A., Adjuvant chemotherapy for advanced endometrial cancer. The Cochrane Collaboration, (eds.) Cochrane Database Syst. Rev, 2014, Chichester, UK, John Wiley & Sons, Ltd, 10.1002/14651858.CD010681.pub2.
23. Acharya, S., Perkins, S.M., DeWees, T., Fischer-Valuck, B.W., Mutch, D.G., Powell, M.A., et al. Brachytherapy is associated with improved survival in inoperable stage I endometrial adenocarcinoma: a population-based analysis. Int. J. Radiat. Oncol. Biol. Phys. 93 (2015), 649–657, 10.1016/j.ijrobp.2015.06.013.
24. Crosby, M.A., Tward, J.D., Szabo, A., Lee, C.M., Gaffney, D.K., Does brachytherapy improve survival in addition to external beam radiation therapy in patients with high risk stage I and II endometrial carcinoma?. Am. J. Clin. Oncol. 33 (2010), 364–369, 10.1097/COC.0b013e3181b0c266.
25. Elshaikh, M.A., Vance, S., Suri, J.S., Mahan, M., Munkarah, A., Improved survival endpoints with adjuvant radiation treatment in patients with high-risk early-stage endometrial carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 88 (2014), 351–356, 10.1016/j.ijrobp.2013.11.003.
26. Nagar, H., Yan, W., Parashar, B., Nori, D., Chao, K.S.C., Christos, P., et al. Adjuvant pelvic radiation therapy ± vaginal brachytherapy in patients with high-risk stage I or stage II uterine papillary serous, clear cell, and high-grade endometrioid carcinoma. Am. J. Clin. Oncol. 39 (2016), 335–339, 10.1097/COC.0000000000000065.
27. Rossi, P.J., Jani, A.B., Horowitz, I.R., Johnstone, P.A.S., Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis. Int. J. Radiat. Oncol. Biol. Phys. 70 (2008), 134–138, 10.1016/j.ijrobp.2007.05.048.
28. Long, B., Liu, F.W., Bristow, R.E., Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States. Gynecol. Oncol. 130 (2013), 652–659, 10.1016/j.ygyno.2013.05.020.
29. Farley, J.H., Tian, C., Rose, G.S., Brown, C.L., Birrer, M., Risinger, J.I., et al. Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a gynecologic oncology group study. Cancer 116 (2010), 355–361, 10.1002/cncr.24769.
30. Talhouk, A., McConechy, M.K., Leung, S., Yang, W., Lum, A., Senz, J., et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer: molecular classification of EC. Cancer 123 (2017), 802–813, 10.1002/cncr.30496.
31. Fedewa, S.A., Lerro, C., Chase, D., Ward, E.M., Insurance status and racial differences in uterine cancer survival: a study of patients in the National Cancer Database. Gynecol. Oncol. 122 (2011), 63–68, 10.1016/j.ygyno.2011.03.010.
32. Bregar, A.J., Alejandro Rauh-Hain, J., Spencer, R., Clemmer, J.T., Schorge, J.O., Rice, L.W., et al. Disparities in receipt of care for high-grade endometrial cancer: a National Cancer Data Base analysis. Gynecol. Oncol. 145 (2017), 114–121, 10.1016/j.ygyno.2017.01.024.